This clinical trial is focused on studying chronic heart failure with reduced ejection fraction, a condition where the heart is unable to pump blood effectively, leading to symptoms like fatigue and shortness of breath. The study will use a medication called vericiguat, also known by its code name BAY 1021189. Vericiguat is taken as a film-coated tablet and is being tested to see how well patients tolerate a starting dose of 5 milligrams.

The purpose of the study is to evaluate the tolerability of this starting dose in participants with chronic heart failure. Participants will begin with a 5 mg dose of vericiguat and continue for a period of two weeks. During this time, researchers will monitor the participants to ensure they can complete the two-week course without stopping the medication due to side effects or experiencing moderate to severe low blood pressure, known as hypotension.

The study will also observe any adverse effects, which are unwanted symptoms or reactions, that may occur between the start and end of the two-week period. The goal is to ensure that participants can continuously take the medication or resume it if there is any temporary interruption. This trial aims to provide valuable information on the safety and tolerability of vericiguat for individuals with chronic heart failure with reduced ejection fraction.